2; SD = 15 8; Sandoz et al , 2013)

2; SD = 15.8; Sandoz et al., 2013). Selleckchem MAPK Inhibitor Library The pretreatment score suggested that her negative body image interfered with her daily activities to a significant degree at pretreatment. At the midpoint of therapy, her body image flexibility score increased to 67, which fell within the average range of a nonclinical sample, and it remained within the average range at posttreatment. Her average

body image flexibility score throughout the course of the ACT intervention was 57.8 and 53 at 3-month follow-up. Participant 1’s scores on disordered eating related measures administered at pretreatment, midpoint, posttreatment, and 3-month follow-up were generally consistent with the findings of the primary outcome and process measures. Participant 2’s daily report revealed that the average weekly number of binge eating was approximately 8 at pretreatment, which was consistent with the diagnostic criteria for BED. During the 10 weeks of the ACT intervention, the average number of binge episodes decreased to approximately 4.6 times per week, which still met the minimum number of binge episodes required for a BED diagnosis (i.e., approximately twice per week). At the 3-month follow-up period, the average number of AZD8055 binge episodes was approximately 3 times per week. Participant 2’s body image flexibility levels throughout the course of the study revealed a similar

clinical picture. Her body image flexibility score was 28 at pretreatment, which was more than two standard deviations below the mean for a nonclinical sample. Her body image flexibility score improved slightly throughout the course of the ACT intervention, with a weekly average of 35.5, and the improvement was somewhat maintained at follow-up (33). Similarly, Participant 2’s scores on disordered eating related measures suggested that her disordered eating concerns decreased but remained relatively elevated throughout the study. Notably, the participant greatly reduced the amount of time spent overeating with a sense of having lost control over eating throughout the course of study. She endorsed oxyclozanide engaging in episodes of consuming unusually large amounts of food

at a clinically significant level; however, the number of episodes that were accompanied by a perceived loss of control over eating was 20% at midpoint compared to 100% of the time at pretreatment. This ratio remained at lower levels at posttreatment and follow-up. When asked about the change at posttreatment and follow-up, Participant 2 attributed it to a decrease in the amount of food she consumed during a “binge” episode. While she still considered her food consumption during “binge” episodes to be “unusually large,” the amount she consumed in an episode appeared to have become smaller since the midpoint of therapy. For example, a “binge” for this participant after midpoint might include eating two cheeseburgers and an order of french-fries from a fast food restaurant.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>